Adrian Howd, Ph.D.

  • Chief Executive Officer at Malin Corporation plc
  • Previously with Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research
  • Also previously Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG
  • Ph.D. in molecular neuroscience from the University of London and is a principal, director and shareholder of Brandon Point Industries

Kelly Martin

  • Interim CEO of Novan, Inc.
  • Previously served as CEO of Malin Corporation plc and Elan from 2003 until December 2013
  • More than 20 years at Merrill Lynch & Co. Inc. prior to Elan
  • Non-executive director on a number of public and private company boards and co-founder, director and shareholder of Brandon Point Industries

Lars Ekman, M.D., Ph.D.         

  • Executive Partner at Sofinnova Ventures
  • Over 28 years in senior executive, scientific, and clinical functions
  • Over 8 NDAs filed
  • Former President of R&D at Elan, EVP, R&D at Schwarz Pharma AG, and a variety of senior scientific and clinical functions at Pharmacia, now Pfizer

Eric Ostertag, M.D., Ph.D.

  • Poseida Chief Executive Officer

Nishan de Silva, M.D.

  • Poseida President and Chief Operating Officer